Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI Global Longevity Bio Index (KGLB)
6/1/2026, 12:00:00 AM
Announced that the CARES Phase III clinical program for anselamimab, a treatment for light chain amyloidosis, did not meet its primary endpoint in the overall patient population. High importance estimated due to the failure of a late-stage clinical trial.
Korean Translation
경쇄 아밀로이드증 치료제인 안셀라미맙(anselamimab)의 CARES 3상 임상 프로그램이 전체 환자군에서 1차 평가변수를 충족하지 못했다고 발표함. 후기 임상 시험 실패로 인해 높은 중요도로 평가함.
Related Recent Events
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for a decision on the approval of the seasonal flu vaccine candidate (mRNA-1010) is scheduled for 2026-08-05, which is estimated to cause a ≥5% price impact scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
GSK plc (GSK) · Earnings Release
GSK's second quarter 2026 earnings release scheduled. Routine earnings releases typically result in a price impact of approximately 1-3%.
7/28/2026, 12:00:00 AM
Revvity Inc (RVTY) · Earnings Release
Revvity's Q2 2026 earnings release is scheduled for 2026-07-27.
7/27/2026, 12:00:00 AM